FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072300370> ?p ?o ?g. }

• W2072300370 endingPage "19797" @default.
• W2072300370 startingPage "19793" @default.
• W2072300370 abstract "Gain-of-function mutants of Ras and Rho family small GTPases have proven to be important tools in analyzing signaling downstream of these small GTPases. The Ras-related GTPase Rheb has emerged as a key player downstream of TSC1–2 in activating signaling to mammalian target of rapamycin (mTOR) effectors of cell growth such as S6K and 4E-BP1. The TSC1–2 tumor suppressor complex has been shown to act as a RhebGAP, converting Rheb from a GTP-bound to a GDP-bound form. Here we report the identification of a mutant Rheb (S16HRheb) that exhibits gain-of-function properties. At endogenous levels of expression S16HRheb exhibits increased GTP loading in vivo and is resistant to TSC1–2 GAP in vitro. Compared with wild-type Rheb, S16HRheb is more active at promoting the phosphorylation of the mTOR effectors S6K1 and 4E-BP1. Thus S16HRheb will help to identify proximal signaling events downstream of Rheb and allow potential Rheb-independent functions downstream of TSC1–2 to be investigated. Gain-of-function mutants of Ras and Rho family small GTPases have proven to be important tools in analyzing signaling downstream of these small GTPases. The Ras-related GTPase Rheb has emerged as a key player downstream of TSC1–2 in activating signaling to mammalian target of rapamycin (mTOR) effectors of cell growth such as S6K and 4E-BP1. The TSC1–2 tumor suppressor complex has been shown to act as a RhebGAP, converting Rheb from a GTP-bound to a GDP-bound form. Here we report the identification of a mutant Rheb (S16HRheb) that exhibits gain-of-function properties. At endogenous levels of expression S16HRheb exhibits increased GTP loading in vivo and is resistant to TSC1–2 GAP in vitro. Compared with wild-type Rheb, S16HRheb is more active at promoting the phosphorylation of the mTOR effectors S6K1 and 4E-BP1. Thus S16HRheb will help to identify proximal signaling events downstream of Rheb and allow potential Rheb-independent functions downstream of TSC1–2 to be investigated. The TSC1–2 tumor suppressor complex acts to negatively regulate mTOR 2The abbreviations used are: mTOR, mammalian target of rapamycin; HA, hemagglutinin; GST, glutathione S-transferase; GAP, GTPase-activating protein.2The abbreviations used are: mTOR, mammalian target of rapamycin; HA, hemagglutinin; GST, glutathione S-transferase; GAP, GTPase-activating protein. signaling, with loss of function in humans responsible for the benign hamartomatous syndrome, tuberous sclerosis complex, and increased cell number and cell and organ growth in Drosophila (reviewed in Ref. 1.Findlay G.M. Harrington L.S. Lamb R.F. Curr. Opin. Genet. Dev. 2005; 15: 69-76Crossref PubMed Scopus (33) Google Scholar). Genetic screens in Drosophila have identified Rheb as a critical regulator of growth, and both genetic and biochemical evidence indicates that TSC1–2 inhibits Rheb and suppresses growth by acting as a RhebGAP (2.Patel P.H. Thapar N. Guo L. Martinez M. Maris J. Gau C.L. Lengyel J.A. Tamanoi F. J. Cell Sci. 2003; 116: 3601-3610Crossref PubMed Scopus (126) Google Scholar, 3.Saucedo L.J. Gao X. Chiarelli D.A. Li L. Pan D. Edgar B.A. Nat. Cell Biol. 2003; 5: 566-571Crossref PubMed Scopus (524) Google Scholar, 4.Stocker H. Radimerski T. Schindelholz B. Wittwer F. Belawat P. Daram P. Breuer S. Thomas G. Hafen E. Nat. Cell Biol. 2003; 5: 559-565Crossref PubMed Scopus (423) Google Scholar). Both TSC1 and TSC2 appear necessary for RhebGAP activity (5.Tee A.R. Manning B.D. Roux P.P. Cantley L.C. Blenis J. Curr. Biol. 2003; 13: 1259-1268Abstract Full Text Full Text PDF PubMed Scopus (922) Google Scholar) and a so-called “asparagine thumb” involving Asn1643 of the TSC2 GAP domain, has been suggested to participate in GTP hydrolysis (6.Li Y. Inoki K. Guan K.L. Mol. Cell. Biol. 2004; 24: 7965-7975Crossref PubMed Scopus (186) Google Scholar), analogous to the regulation of Rap1 by RapGAP (7.Daumke O. Weyand M. Chakrabarti P.P. Vetter I.R. Wittinghofer A. Nature. 2004; 429: 197-201Crossref PubMed Scopus (114) Google Scholar). Consistent with this notion, this residue is mutated in tuberous sclerosis complex (8.Maheshwar M.M. Cheadle J.P. Jones A.C. Myring J. Fryer A.E. Harris P.C. Sampson J.R. Hum. Mol. Genet. 1997; 6: 1991-1996Crossref PubMed Scopus (121) Google Scholar) and renders TSC1–2 unable to regulate mTOR signaling to S6K1 (9.Jaeschke A. Hartkamp J. Saitoh M. Roworth W. Nobukuni T. Hodges A. Sampson J. Thomas G. Lamb R. J. Cell Biol. 2002; 159: 217-224Crossref PubMed Scopus (181) Google Scholar). Although loss of function of Rheb is epistatic to TSC1–2 loss of function in Drosophila in regulation of growth (4.Stocker H. Radimerski T. Schindelholz B. Wittwer F. Belawat P. Daram P. Breuer S. Thomas G. Hafen E. Nat. Cell Biol. 2003; 5: 559-565Crossref PubMed Scopus (423) Google Scholar), it is unclear why loss of function of TSC1–2 promotes increased cell number in Drosophila (10.Tapon N. Ito N. Dickson B.J. Treisman J.E. Hariharan I.K. Cell. 2001; 105: 345-355Abstract Full Text Full Text PDF PubMed Scopus (448) Google Scholar), while gain-of-function of Rheb by overexpression does not (4.Stocker H. Radimerski T. Schindelholz B. Wittwer F. Belawat P. Daram P. Breuer S. Thomas G. Hafen E. Nat. Cell Biol. 2003; 5: 559-565Crossref PubMed Scopus (423) Google Scholar). A possible explanation is that TSC1–2 has targets in addition to Rheb involved in regulating cell number. To help clarify this issue it will be necessary to compare phenotypes of TSC1–2 deficiency with that of Rheb rendered insensitive to TSC1–2 GAP. In K-Ras, gain-of-function mutations in codon 12 have been generated at endogenous levels in conditional mouse models resulting in tumor phenotypes analogous to human cancers in which mutation of these residues are found (11.Johnson L. Mercer K. Greenbaum D. Bronson R.T. Crowley D. Tuveson D.A. Jacks T. Nature. 2001; 410: 1111-1116Crossref PubMed Scopus (934) Google Scholar, 12.Braun B.S. Tuveson D.A. Kong N. Le D.T. Kogan S.C. Rozmus J. Le Beau M.M. Jacks T.E. Shannon K.M. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 597-602Crossref PubMed Scopus (257) Google Scholar). However, the functional consequences of similar mutations in Rheb are not known. Here we report the analysis of a Rheb mutant (S16HRheb) that exhibits gain-of-function properties similar to that of V12Ras in the activation of mTOR signaling to S6K and 4E-BP1. Plasmid Constructs—pRK5myc-Rheb and pGEX-4T2-Rheb constructs were generated by reverse transcription-PCR using Rheb-specific primers to clone Rheb from human brain cDNA (Clontech). Mutant Rhebs in pRK5myc or pGEX-4T2 were obtained using a QuikChange site-directed mutagenesis kit (Stratagene). pEGFPN1TSC1 has been described (13.Lamb R.F. Roy C. Diefenbach T.J. Vinters H.V. Johnson M.W. Jay D.G. Hall A. Nat. Cell Biol. 2000; 2: 281-287Crossref PubMed Scopus (277) Google Scholar); pCMV-FLAG-TSC1 and pCMV-TSC2, pCDNA3HA-4E-BP1, and pRK5S6K-GST were provided, respectively, by Dr. Julian Sampson, Dr. Nahum Sonenberg, and Dr. George Thomas. Cell Culture, Transfection, and Immunoblotting—HEK293T cells were transfected with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. For experiments with S6K or 4E-BP1 reporter plasmids cells were lysed in lysis buffer (50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 1% Triton X-100, 50 mm NaF, 1 mm NaOV, 1 mm EDTA, 1 mm EGTA, 0.27 m sucrose, 5 mm MgCl2, 0.1% β-mercaptoethanol, and Complete proteinase inhibitors (Roche Applied Science). For 4E-BP1 experiments blots were fixed in 0.2% glutaraldehyde after transfer. Commercial antibodies were as follows: anti-FLAG M2 (Sigma), anti-phospho-Thr389-S6K, anti-HA, and anti-phospho-Ser65 4E-BP1 (Cell Signaling Technology) and anti-S6K1 monoclonal (Transduction Laboratories). Rabbit anti-human Rheb was generated by immunizing rabbits with GST-Rheb and affinity purified with GST-Rheb chemically cross-linked to glutathione-agarose. In Vivo Rheb Guanine Nucleotide Binding—HEK293T in 10-cm2 plates were transfected using Lipofectamine 2000. Forty hours after transfection, cells were washed once with phosphate-free Dulbecco's modified Eagle's medium (Invitrogen), incubated with phosphate-free Dulbecco's modified Eagle's medium for 2 h, and labeled with 0.1 mCi of [32P]orthophosphate (Amersham Biosciences)/ml for 4 h. Cells harvested as described (14.Wolthuis R.M. de Ruiter N.D. Cool R.H. Bos J.L. EMBO J. 1997; 16: 6748-6761Crossref PubMed Scopus (144) Google Scholar) were centrifuged for 10 min at 14,000 rpm at 4 °C and lysates adjusted to 0.5 m NaCl prior to immunoprecipitation with 5 μg 9E10 anti-myc antibody and protein G-Sepharose beads for 2 h. Beads were washed and nucleotides eluted and resolved by TLC as described (14.Wolthuis R.M. de Ruiter N.D. Cool R.H. Bos J.L. EMBO J. 1997; 16: 6748-6761Crossref PubMed Scopus (144) Google Scholar). [32P]GTP and [32P]GDP levels were imaged and quantified on a PhosphorImager using ImageQuant software (Amersham Biosciences). In Vitro GAP Assays—5 × 106 HEK 293T cells were transfected with 20 μg each of pEGFPN1TSC1 and pCMV FLAG TSC2 or with empty vector using Lipofectamine 2000. Cells were incubated for 44 h, the last 24 h being in serum-free medium and lysis and assays performed as described (5.Tee A.R. Manning B.D. Roux P.P. Cantley L.C. Blenis J. Curr. Biol. 2003; 13: 1259-1268Abstract Full Text Full Text PDF PubMed Scopus (922) Google Scholar). Guanine nucleotides were quantified using ImageQuant software (Amersham Biosciences). We reasoned that in organisms such as budding yeast Saccharomyces cerevisiae and Caenorhabditis elegans lacking TSC1–2, but encoding orthologues of Rheb, there would be no selective pressure to maintain sensitivity to TSC1–2 GAP activity. Thus residues that are conserved in Rheb from species containing TSC1–2, but divergent in both S. cerevisiae and C. elegans, could potentially render Rheb sensitive to TSC1–2 action. By aligning protein sequences in ClustalW, we identified three residues (serines 16 and 89 and threonine 42 in human Rheb) that are conserved in organisms that contain TSC1–2 but have diverged in both S. cerevisiae and C. elegans (Fig. 1A). Our attention was drawn to one of these positions, Ser16, for two reasons. First, in Ras this position is equivalent to glycine at codon 13, a residue that is subject to oncogenic mutations that are thought to render Ras resistant to GAP-stimulated hydrolysis (15.Barbacid M. Annu. Rev. Biochem. 1987; 56: 779-827Crossref PubMed Scopus (3748) Google Scholar). Second, this residue is immediately adjacent to arginine 15 (Arg15), a residue that, when mutated to glycine (R15G), has been reported to render Rheb more highly GTP loaded and partially resistant to TSC1–2 GAP activity in vivo (6.Li Y. Inoki K. Guan K.L. Mol. Cell. Biol. 2004; 24: 7965-7975Crossref PubMed Scopus (186) Google Scholar). A recent report using PCR-based mutagenesis and genetic screening has also identified three mutations in Schizosaccharomyces pombe Rheb (equivalent to V17G, K120R, and N153S in human Rheb) that potentially exhibit gain-of-function properties (16.Urano J. Comiso M.J. Guo L. Aspuria P.J. Deniskin R. Tabancay Jr., A.P. Kato-Stankiewicz J. Tamanoi F. Mol. Microbiol. 2005; 58: 1074-1086Crossref PubMed Scopus (76) Google Scholar). However, whether analogous mutations increase the ability of mammalian Rheb to activate mTOR signaling is not known. As an initial screen for function and sensitivity to TSC1–2 action therefore we expressed wild-type or Rheb mutated at Arg15 (R15G), Ser16 (S16H and S16N), and Ser89 (S89D, S89N) as well as the equivalent mutations identified in S. pombe (N153S, V17G, K120R) as myc-tagged proteins alone or together with TSC1–2 along with an S6K-GST reporter in HEK293T cells. Overexpression of wild-type Rheb strongly stimulates the phosphorylation of S6K1 at T389, a residue required for S6 kinase activity (Fig. 1b). In the absence of overexpressed TSC1–2, S16H, S16N, and N153S activate S6K more potently than the other mutants or wild-type Rheb. When TSC1–2 is overexpressed we obtain similar results: S16H, S16N, and N153S all remain able to strongly activate S6K activation (S16H > S16N > N153S, see supplemental Fig. S1). However, both R15G and V17G are suppressed by TSC1–2 as strongly as wild-type Rheb, while K120R and both S89D and S89N show partial resistance to overexpressed TSC1–2. To confirm that the increased ability of S16HRheb to activate S6K1 T389 phosphorylation in the presence of TSC1–2 is due to the inability of TSC1–2 to stimulate GTP hydrolysis of this mutant, we examined the in vivo guanine nucleotide loading of wild-type and Rheb mutant proteins. Constructs encoding myc-tagged wild-type Rheb, R15G, S16H, and N153S were transfected alone or together with FLAG-tagged TSC1 and TSC2 into HEK293T cells, which were labeled with 32P, and Rheb proteins immunoprecipitated and bound guanine nucleotides analyzed. The results show that of the three mutants analyzed in the absence of overexpressed TSC1–2 S16HRheb exhibits the highest GTP loading (83% ± 4 for S16H compared with 64% ± 6 for wild-type Rheb, p < 0.02, n = 3). In the presence of TSC1–2 both R15GRheb and N153SRheb exhibit slightly reduced sensitivity to TSC1–2 compared with wild-type Rheb, while S16HRheb exhibits the least sensitivity to TSC1–2 (remaining 55 ± 3% GTP bound compared with 27 ± 5% for wild-type Rheb, Fig. 2, A and B, p < 0.005, n = 3). Consistent with failure of S16HRheb to be regulated by TSC1–2, when expressed at endogenous levels in serum-starved HEK293T cells, FLAG epitope-tagged S16HRheb exhibits a 2-fold increase in GTP loading compared with wild-type Rheb (see supplemental Fig. S2). At this level of expression it was not possible to analyze the bound guanine nucleotides of the N153S and R15G mutants as they immunoprecipitated poorly. To characterize further the S16H mutation we examined both binding and dissociation of guanine nucleotides. Surprisingly, although more highly GTP loaded in vivo than wild type, S16HRheb exhibits slightly reduced binding to both GDP and GTP and a slightly increased rate of dissociation of both nucleotides (see supplemental Fig. S3). To explore whether instead the mutation affects GTP hydrolysis, we performed in vitro GAP assays with recombinant GST-Rheb and GST-S16HRheb (Fig. 2C). Significantly, the hydrolysis of wild-type GST-Rheb, but not S16HRheb, is strongly stimulated by TSC1–2 GAP activity (wild-type Rheb remaining 2.2 ± 0.2% GTP bound; S16H Rheb 88.8 ± 0.8% GTP bound, Fig. 2, C–E). In addition, S16HRheb exhibits a small reduction in intrinsic GTP hydrolysis compared with wild-type Rheb (89.4 ± 0.4% GTP bound versus 79.8 ± 1.8%, p < 0.002, n = 3). Identical results are obtained using a charcoal-release assay in which the release of [32P]Pi is measured (see supplemental Fig. S4). Thus the S16H mutation confers resistance to TSC1–2 GAP activity in vitro. These results suggest that at endogenous levels S16HRheb may be insensitive to TSC1–2 and therefore behave as a gain-of-function mutant in activating mTOR signaling. To explore this possibility, we performed a titration experiment expressing myc-tagged wild-type or S16HRheb at different levels along with reporter plasmids for S6K1 (S6K1-GST) and 4E-BP1 (HA-4E-BP1) and determined the phosphorylations of S6K1-T389 and 4E-BP1 S65, both of which have been shown to be stimulated by TSC1–2 deficiency and Rheb overexpression (17.Garami A. Zwartkruis F.J. Nobukuni T. Joaquin M. Roccio M. Stocker H. Kozma S.C. Hafen E. Bos J.L. Thomas G. Mol. Cell. 2003; 11: 1457-1466Abstract Full Text Full Text PDF PubMed Scopus (823) Google Scholar, 18.Tee A.R. Blenis J. Proud C.G. FEBS Lett. 2005; 579: 4763-4768Crossref PubMed Scopus (83) Google Scholar). The results show that, when expressed at levels close to endogenous Rheb (around 8 ng of transfected plasmid), wild-type Rheb does not promote S6K1 reporter T389 phosphorylation in serum-starved HEK293T cells, while S16HRheb remains able to stimulate T389 phosphorylation (Fig. 3A). For the 4E-BP1 reporter, wild-type Rheb poorly stimulates phosphorylation at Ser65 at the expression levels used (up to 250 ng of plasmid) compared with the S6K1 reporter. However, S16HRheb is still able to strongly promote phosphorylation at this level of expression and at an increased level compared with wild-type Rheb down to as low as 8 ng of plasmid of transfected plasmid (Fig. 3B). Thus when expressed at endogenous levels S16HRheb exhibits gain-of-function properties in promoting the phosphorylation of two downstream effectors of mTOR. The structures of Rheb complexed to GTP and GDP have recently been determined indicating a structural alteration of the switch 1 effector loop upon GTP binding (19.Yu Y. Li S. Xu X. Li Y. Guan K. Arnold E. Ding J. J. Biol. Chem. 2005; 280: 17093-17100Abstract Full Text Full Text PDF PubMed Scopus (62) Google Scholar). However, the structure of Rheb in the transition state of GTP hydrolysis when complexed to TSC1–2 is not known. Thus it is difficult to assess how the Ser16 → His substitution inhibits TSC1–2 action. However, in the structure of H-Ras complexed to GDP, AlF3 and GAP-334, a mimic of the transition state of Ras during GTP hydrolysis, it is clear that weak interactions occur between the Cα atom of Gly12 of Ras and the main chain CO of Arg789 of GAP. Thus it has been proposed that this mode of interaction renders most mutations at Gly12 resistant to GAP and therefore oncogenic (20.Scheffzek K. Ahmadian M.R. Kabsch W. Wiesmuller L. Lautwein A. Schmitz F. Wittinghofer A. Science. 1997; 277: 333-338Crossref PubMed Scopus (1162) Google Scholar). It is plausible therefore that in the transition state of GTP hydrolysis interactions involving Ser16 of Rheb and N1643 of the TSC2 GAP limit the substitutions at Ser16 that permit efficient hydrolysis of GTP. Interestingly, substitution of Ser16 by glycine has reported not to affect Rheb GTP loading (21.Im E. von Lintig F.C. Chen J. Zhuang S. Qui W. Chowdhury S. Worley P.F. Boss G.R. Pilz R.B. Oncogene. 2002; 21: 6356-6365Crossref PubMed Scopus (116) Google Scholar), suggesting that the bulky imidazole ring of histidine in this position may be critical in preventing TSC1–2 GAP action. Since S16HRheb activates mTOR signaling to S6K and 4E-BP1 when expressed at low levels, it may prove to be a useful tool in identifying effector mechanisms coupling Rheb.GTP to mTOR signaling and help to identify potential Rheb-independent functions of TSC1–2. We thank Nahum Sonenberg, George Thomas, and Julian Sampson for gifts of plasmids; Christopher Proud for advice on 4E-BP1 immunoblotting; and Christopher Marshall for discussion and critical reading of the manuscript. Download .pdf (.23 MB) Help with pdf files" @default.
• W2072300370 created "2016-06-24" @default.
• W2072300370 creator A5000258587 @default.
• W2072300370 creator A5011692149 @default.
• W2072300370 creator A5018829184 @default.
• W2072300370 creator A5049624212 @default.
• W2072300370 creator A5061522131 @default.
• W2072300370 creator A5089149405 @default.
• W2072300370 date "2006-07-01" @default.
• W2072300370 modified "2023-10-13" @default.
• W2072300370 title "Hyperactivation of Mammalian Target of Rapamycin (mTOR) Signaling by a Gain-of-Function Mutant of the Rheb GTPase" @default.
• W2072300370 cites W1555102770 @default.
• W2072300370 cites W1611210979 @default.
• W2072300370 cites W1877343178 @default.
• W2072300370 cites W1968453436 @default.
• W2072300370 cites W1983247384 @default.
• W2072300370 cites W1992864103 @default.
• W2072300370 cites W1998277565 @default.
• W2072300370 cites W2011872098 @default.
• W2072300370 cites W2017349699 @default.
• W2072300370 cites W2032685334 @default.
• W2072300370 cites W2044247583 @default.
• W2072300370 cites W2057779613 @default.
• W2072300370 cites W2081526354 @default.
• W2072300370 cites W2082853003 @default.
• W2072300370 cites W2109263914 @default.
• W2072300370 cites W2117257231 @default.
• W2072300370 cites W2139112892 @default.
• W2072300370 cites W2139752122 @default.
• W2072300370 cites W2153552867 @default.
• W2072300370 cites W2166606571 @default.
• W2072300370 cites W4232777855 @default.
• W2072300370 doi "https://doi.org/10.1074/jbc.c600028200" @default.
• W2072300370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16728407" @default.
• W2072300370 hasPublicationYear "2006" @default.
• W2072300370 type Work @default.
• W2072300370 sameAs 2072300370 @default.
• W2072300370 citedByCount "60" @default.
• W2072300370 countsByYear W20723003702012 @default.
• W2072300370 countsByYear W20723003702013 @default.
• W2072300370 countsByYear W20723003702014 @default.
• W2072300370 countsByYear W20723003702015 @default.
• W2072300370 countsByYear W20723003702016 @default.
• W2072300370 countsByYear W20723003702017 @default.
• W2072300370 countsByYear W20723003702018 @default.
• W2072300370 countsByYear W20723003702019 @default.
• W2072300370 countsByYear W20723003702020 @default.
• W2072300370 countsByYear W20723003702021 @default.
• W2072300370 countsByYear W20723003702022 @default.
• W2072300370 countsByYear W20723003702023 @default.
• W2072300370 crossrefType "journal-article" @default.
• W2072300370 hasAuthorship W2072300370A5000258587 @default.
• W2072300370 hasAuthorship W2072300370A5011692149 @default.
• W2072300370 hasAuthorship W2072300370A5018829184 @default.
• W2072300370 hasAuthorship W2072300370A5049624212 @default.
• W2072300370 hasAuthorship W2072300370A5061522131 @default.
• W2072300370 hasAuthorship W2072300370A5089149405 @default.
• W2072300370 hasConcept C104317684 @default.
• W2072300370 hasConcept C14036430 @default.
• W2072300370 hasConcept C143065580 @default.
• W2072300370 hasConcept C185592680 @default.
• W2072300370 hasConcept C207332259 @default.
• W2072300370 hasConcept C2777921159 @default.
• W2072300370 hasConcept C2778366672 @default.
• W2072300370 hasConcept C2778937405 @default.
• W2072300370 hasConcept C2780298669 @default.
• W2072300370 hasConcept C2909523446 @default.
• W2072300370 hasConcept C43060935 @default.
• W2072300370 hasConcept C502942594 @default.
• W2072300370 hasConcept C55493867 @default.
• W2072300370 hasConcept C62478195 @default.
• W2072300370 hasConcept C86554907 @default.
• W2072300370 hasConcept C86803240 @default.
• W2072300370 hasConcept C95444343 @default.
• W2072300370 hasConcept C98490376 @default.
• W2072300370 hasConceptScore W2072300370C104317684 @default.
• W2072300370 hasConceptScore W2072300370C14036430 @default.
• W2072300370 hasConceptScore W2072300370C143065580 @default.
• W2072300370 hasConceptScore W2072300370C185592680 @default.
• W2072300370 hasConceptScore W2072300370C207332259 @default.
• W2072300370 hasConceptScore W2072300370C2777921159 @default.
• W2072300370 hasConceptScore W2072300370C2778366672 @default.
• W2072300370 hasConceptScore W2072300370C2778937405 @default.
• W2072300370 hasConceptScore W2072300370C2780298669 @default.
• W2072300370 hasConceptScore W2072300370C2909523446 @default.
• W2072300370 hasConceptScore W2072300370C43060935 @default.
• W2072300370 hasConceptScore W2072300370C502942594 @default.
• W2072300370 hasConceptScore W2072300370C55493867 @default.
• W2072300370 hasConceptScore W2072300370C62478195 @default.
• W2072300370 hasConceptScore W2072300370C86554907 @default.
• W2072300370 hasConceptScore W2072300370C86803240 @default.
• W2072300370 hasConceptScore W2072300370C95444343 @default.
• W2072300370 hasConceptScore W2072300370C98490376 @default.
• W2072300370 hasIssue "29" @default.
• W2072300370 hasLocation W20723003701 @default.
• W2072300370 hasOpenAccess W2072300370 @default.
• W2072300370 hasPrimaryLocation W20723003701 @default.
• W2072300370 hasRelatedWork W1977077130 @default.

• next